Synonyms that are in the dictionary are marked in green. Synonyms that are not in the dictionary are marked in red.
Antonyms that are in the dictionary are marked in green. Antonyms that are not in the dictionary are marked in red.
Bank of America boosted their price objective on Catalent from $28.00 to $33.00 in a report on Tuesday, June 13th.
Source: https://www.etfdailynews.com/2023/08/28/catalent-inc-nysectlt-evp-sells-36479-05-in-stock/
Bank of America downgraded Catalent from a “buy” rating to a “neutral” rating and cut their target price for the stock from $125.00 to $60.00 in a report on Wednesday, November 2nd.
Barclays dropped their target price on shares of Catalent from $40.00 to $35.00 in a research note on Sunday.
Based on data from MarketBeat, Catalent presently has a consensus rating of Hold and an average target price of $53.
Source: https://www.etfdailynews.com/2023/09/09/argus-upgrades-catalent-nysectlt-to-buy/
Catalent has a 52 week low of $31.45 and a 52 week high of $97.54.
Source: https://www.etfdailynews.com/2023/09/09/argus-upgrades-catalent-nysectlt-to-buy/
Catalent, Inc. has a one year low of $31.45 and a one year high of $115.08.
Finally, Vanguard Group Inc. boosted its holdings in shares of Catalent by 2.7% in the 1st quarter.
Source: https://www.etfdailynews.com/2023/01/27/catalent-inc-nysectlt-insider-sells-31738-48-in-stock/
FNY Investment Advisers LLC bought a new stake in shares of Catalent in the 1st quarter valued at approximately $34,000.
FNY Investment Advisers LLC purchased a new position in shares of Catalent in the 1st quarter valued at approximately $34,000.
KB Financial Partners LLC acquired a new position in shares of Catalent in the first quarter valued at approximately $30,000.
Key players profiled include AGC Biologics, Charles River Laboratories, Catalent, Danaher (Cytiva), Lonza, Merck KGaA, and others, contributing to the market's evolution.
Robert W. Baird boosted their price objective on shares of Catalent from $35.00 to $47.00 in a research report on Tuesday, June 13th.
Robert W. Baird raised Catalent from a “neutral” rating to an “outperform” rating and lifted their price target for the company from $45.00 to $53.00 in a report on Thursday, November 16th.
These schemes gave Catalent the appearance of continued growth, causing its stock price to reach record highs.
William Blair restated a market perform rating on shares of Catalent in a research report on Tuesday, November 14th.
Source: https://www.etfdailynews.com/2023/12/11/catalent-nysectlt-issues-fy-2024-earnings-guidance/
Xponance Inc.’s holdings in Catalent were worth $1,722,000 as of its most recent SEC filing.
Source: https://www.etfdailynews.com/2023/01/06/catalent-inc-nysectlt-position-boosted-by-xponance-inc/
Yousif Capital Management LLC trimmed its position in Catalent, Inc. () by 15.0% in the first quarter, Holdings Channel.com reports.